VRDN Insider Trading Activity and SEC Form 4 Filings
VRDN insider trading summary
Over the past 12 months, insiders at Viridian Therapeutics, Inc.\DE (VRDN) reported 3 open-market purchases worth $60.0M by 3 insiders and 3 sales worth $419K by 1 insider on SEC Form 4. Net insider buying was $59.6M.
Latest VRDN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignant | Chief Legal Officer | Sell | $103K (4,212 @ $24.50) |
| Aug 19, 2026 | Jennifer Tousignant | Chief Legal Officer | Sell | $245K (10,000 @ $24.50) |
| May 11, 2026 | Fairmount Healthcare Fund II GP LLC | Director | Buy | $20.0M (1,176,470 @ $17.00) |
| May 11, 2026 | Fairmount Healthcare Fund II L.P. | Director | Buy | $20.0M (1,176,470 @ $17.00) |
| May 11, 2026 | Fairmount Funds Management LLC | Director | Buy | $20.0M (1,176,470 @ $17.00) |
| Dec 31, 2025 | Jennifer Tousignant | Chief Legal Officer | Sell | $71K (2,272 @ $31.16) |
| Oct 23, 2025 | Fairmount Funds Management LLC | Director | Buy | $10.0M (454,545 @ $22.00) |
| Oct 23, 2025 | Fairmount Healthcare Fund II GP LLC | Director | Buy | $10.0M (454,545 @ $22.00) |
| Oct 23, 2025 | Fairmount Healthcare Fund II L.P. | Director | Buy | $10.0M (454,545 @ $22.00) |
| Sep 27, 2024 | Thomas W. Beetham | Chief Operating Officer | Buy | $117K (5,000 @ $23.41) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.